Table 3. Association between HGF expression and clinicopathologic features.
| Variables | No. of patients | HGF expression in cancer cells | HGF expression in stromal fibroblasts | ||||
|---|---|---|---|---|---|---|---|
| Low (%) | High (%) | p | Low (%) | High (%) | P | ||
| Gender | |||||||
| Male | 90 | 19 (21.1) | 71 (78.9) | 0.169 | 42 (46.7) | 48 (53.3) | 0.019 |
| Female | 44 | 5 (11.4) | 39 (88.6) | 30 (68.2) | 14 (31.8) | ||
| Age (years) | |||||||
| ≤63 | 72 | 10 (13.9) | 62 (86.1) | 0.194 | 37 (51.4) | 35 (48.6) | 0.561 |
| >63 | 62 | 14 (22.6) | 48 (77.4) | 35 (56.5) | 27 (43.5) | ||
| Pathologic type | |||||||
| Squamous carcinoma | 56 | 15 (26.8) | 41 (73.2) | 0.128 | 28 (50.0) | 28 (50.0) | 0.827 |
| Adenocarcinoma | 65 | 5 (7.7) | 60 (92.3) | 39 (60.0) | 26 (40.0) | ||
| Adenosquamous carcinoma | 7 | 2 (28.6) | 5 (71.4) | 2 (28.6) | 5 (71.4) | ||
| Large cell carcinoma | 6 | 2 (33.3) | 4 (66.7) | 3 (50.0) | 3 (50.0) | ||
| Pathologic differentiation | |||||||
| High | 10 | 0 (0) | 10 (100.0) | 0.001 | 4 (40.0) | 6 (60.0) | 0.897 |
| Median | 91 | 12 (13.2) | 79 (86.8) | 51 (56.0) | 40 (44.0) | ||
| Low | 33 | 12 (36.4) | 21 (63.6) | 17 (51.5) | 16 (48.5) | ||
| Clinical Stage* | |||||||
| I | 34 | 5 (14.7) | 29 (85.3) | 0.898 | 24 (70.6) | 10 (29.4) | 0.005 |
| II | 26 | 6 (23.1) | 20 (76.9) | 16 (61.5) | 10 (38.5) | ||
| IIIA | 74 | 13 (17.6) | 61 (82.4) | 32 (43.2) | 42 (56.8) | ||
| Vascular invasion | |||||||
| Negative | 120 | 21 (17.5) | 99 (82.5) | 0.719 | 66 (55.0) | 54 (45.0) | 0.392 |
| Positive | 14 | 3 (21.4) | 11 (78.6) | 6 (42.9) | 8 (57.1) | ||